Concepedia

Amy Cutrell

AC

Statistics

Publications

20

Citations

2.9K

H-Index

19

Active since

1998

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

Janssen (Belgium)

ViiV Healthcare (United Kingdom)

Sorbonne Université

Amy Cutrell is an author at Research Triangle Park Foundation specializing in antiretroviral therapy, antiviral therapy, and pharmacology.

Publications per year

1998–2023

20

Publications

20

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 464 citations · Full text

, , +14

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

Seth Hetherington, Sue McGuirk, Gwendolyn Powell et al. · Clinical Therapeutics · 2001 · 414 citations

, , +12

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 364 citations

, , +15

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Amy Cutrell, Jonathan Schapiro, Carlo Federico Perno et al. · AIDS · 2021 · 201 citations · Full text

, , +17

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

Cindy Brothers, Jaime E. Hernández, Amy Cutrell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 182 citations

, , +15

1–5 of 20